Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 7.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 313,781 shares of the medical research company’s stock after acquiring an additional 21,824 shares during the period. Janney Montgomery Scott LLC’s holdings in Amgen were worth $89,214,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Klingman & Associates LLC lifted its stake in Amgen by 5.3% during the first quarter. Klingman & Associates LLC now owns 1,248 shares of the medical research company’s stock valued at $355,000 after purchasing an additional 63 shares during the last quarter. Ascent Wealth Partners LLC boosted its stake in shares of Amgen by 136.0% during the 1st quarter. Ascent Wealth Partners LLC now owns 8,829 shares of the medical research company’s stock worth $2,431,000 after acquiring an additional 5,088 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Amgen by 8.3% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 734,632 shares of the medical research company’s stock worth $190,565,000 after acquiring an additional 56,376 shares during the last quarter. Prosperity Consulting Group LLC raised its position in shares of Amgen by 2.3% during the first quarter. Prosperity Consulting Group LLC now owns 6,012 shares of the medical research company’s stock worth $1,709,000 after purchasing an additional 135 shares during the period. Finally, Braun Stacey Associates Inc. lifted its holdings in shares of Amgen by 20.3% during the first quarter. Braun Stacey Associates Inc. now owns 54,685 shares of the medical research company’s stock valued at $15,548,000 after purchasing an additional 9,220 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 2,117 shares of Amgen stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.69% of the company’s stock.

Amgen Stock Up 0.5 %

Shares of AMGN stock traded up $1.50 on Friday, hitting $310.88. The company’s stock had a trading volume of 1,274,377 shares, compared to its average volume of 2,207,024. The stock has a market capitalization of $166.77 billion, a price-to-earnings ratio of 44.41, a P/E/G ratio of 2.79 and a beta of 0.58. Amgen Inc. has a fifty-two week low of $218.44 and a fifty-two week high of $329.72. The firm’s fifty day moving average price is $305.43 and its 200-day moving average price is $293.27. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.76 by $0.20. The company had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The business’s revenue was up 22.0% compared to the same quarter last year. During the same period last year, the company earned $3.98 earnings per share. Research analysts anticipate that Amgen Inc. will post 19.47 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the company. BMO Capital Markets boosted their price objective on Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. UBS Group upped their price target on shares of Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Mizuho raised their price objective on shares of Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a research note on Thursday, May 9th. Barclays raised shares of Amgen from an “underweight” rating to an “equal weight” rating and boosted their target price for the company from $230.00 to $300.00 in a research note on Friday, May 3rd. Finally, Royal Bank of Canada raised their target price on Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a research report on Friday, June 14th. Ten research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $307.35.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.